Publication
A phase 2 trial of dasatinib in advanced melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21523734
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KIT Exon 11 Mutation1 | ||||||||
| Dasatinib | Melanoma | Predictive | C | Supports Resistance | — | submitted | EID4686In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a patient harboring a KIT exon 11 Deletion mutation was reported to have no response to dasatinib monothe… (full text at CIViC) PMID 21523734 · Kluger et al., 2011 · Open in CIViC | civic |
| KIT K642E1 | ||||||||
| Dasatinib | Melanoma | Predictive | C | Supports Sensitivity Response | — | accepted | EID4147In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to … (full text at CIViC) PMID 21523734 · Kluger et al., 2011 · Open in CIViC | civic |
| KIT EXPRESSION1 | ||||||||
| Dasatinib | Ocular Melanoma | Predictive | C | Does Not Support Sensitivity Response | 1 | submitted | EID7758In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients receiving dasatinib without prior biomarker screening, six patients achieved clinical benefit (2 PR; 4 SD)… (full text at CIViC) PMID 21523734 · Kluger et al., 2011 · Open in CIViC | civic |